心通医疗-B(02160)发盈警预期2024年净亏损约3000万-6000万元同比减少约87%至94%

智通财经网03-06

智通财经APP讯，心通医疗-B(02160)公布，该集团预期2024年取得净亏损约人民币3000万-6000万元，同比减少约87%至94%。公告称，预期亏损减少主要是由于：经导管主动脉瓣膜植入术产品VitaFlow®及VitaFlow Liberty®和 AnchorMan®左心耳封堵器系统及其导引系统在中国的商业化有序推进，植入量持续增长;VitaFlow Liberty®经导管主动脉瓣膜...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2517150236?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_37.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","is_english":false,"pubTime":"2025-03-06 21:55","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2517150236","market":"hk","top_or_hot":-1,"title":"心通医疗-B(02160)发盈警 预期2024年净亏损约3000万-6000万元 同比减少约87%至94%","media":"智通财经网","content":"<div>\n<p>智通财经APP讯，心通医疗-B(02160)公布，该集团预期2024年取得净亏损约人民币3000万-6000万元，同比减少约87%至94%。公告称，预期亏损减少主要是由于： 经导管主动脉瓣膜植入术产品VitaFlow®及VitaFlow Liberty®和  AnchorMan®左心耳封堵器系统及其导引系统在中国的商业化有序推进，植入量持续增长;VitaFlow  Liberty®经导管主动脉瓣膜...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1258805.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>心通医疗-B(02160)发盈警 预期2024年净亏损约3000万-6000万元 同比减少约87%至94%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n心通医疗-B(02160)发盈警 预期2024年净亏损约3000万-6000万元 同比减少约87%至94%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-06 21:55 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1258805.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，心通医疗-B(02160)公布，该集团预期2024年取得净亏损约人民币3000万-6000万元，同比减少约87%至94%。公告称，预期亏损减少主要是由于： 经导管主动脉瓣膜植入术产品VitaFlow®及VitaFlow Liberty®和  AnchorMan®左心耳封堵器系统及其导引系统在中国的商业化有序推进，植入量持续增长;VitaFlow  Liberty®经导管主动脉瓣膜...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1258805.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02160","symbol_name":"心通医疗-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1258805.html","article_id":"2517150236","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_37.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517150236","pubTimestamp":1741269335,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"心通医疗-B(02160)公布，该集团预期2024年取得净亏损约人民币3000万-...","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02160":"心通医疗-B","BK1583":"高瓴概念","BK1574":"生物医药B类股","BK1100":"医疗保健设备"},"translate_title":"Xintong Medical-B (02160) issued a profit warning, expecting a net loss of about 30 million to 60 million yuan in 2024, a year-on-year decrease of about 87% to 94%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02160":1},"content_text":"智通财经APP讯，心通医疗-B(02160)公布，该集团预期2024年取得净亏损约人民币3000万-6000万元，同比减少约87%至94%。公告称，预期亏损减少主要是由于： 经导管主动脉瓣膜植入术产品VitaFlow®及VitaFlow Liberty®和  AnchorMan®左心耳封堵器系统及其导引系统在中国的商业化有序推进，植入量持续增长;VitaFlow  Liberty®经导管主动脉瓣膜及可回收输送系统于报告期内获得CE标志，并已在海外17个国家╱地区实现销售，来自海外的收入较2023 年度增长一倍以上。此外，集团以财务报表的健康度为重，聚焦业务，进一步开展降本控费，通过持续优化制造工艺，提升生产效率，多渠道开发材料供方及提高关键物料的利用率等措施降低产品成本;同时，统筹内外部资源、发挥集约效应，通过评估运营费用的投入产出，持续提高运营效率，实现业务的健康可持续增长;基于集团联营公司4C  Medical Technologies, Inc.(4C Medical)于2025年 3月完成的D轮融资，并结合其最新的研发项目进展，对持有的4C  Medical 的股权投资，集团转回了前期计提的减值准备;另外，对持有的4C Medical发行的可转换债券，集团确认了公允价值变动收益。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2517150236"}

心通医疗-B(02160)发盈警 预期2024年净亏损约3000万-6000万元 同比减少约87%至94%

精彩评论

心通医疗-B(02160)发盈警预期2024年净亏损约3000万-6000万元同比减少约87%至94%